Description
Digestix – Reclaim Energy, Fight Long COVID, Fight Covid Vaccine Side-Effects
A Patent-Pending Exploratory IL6 Solution
Apply Coupon Code for 1-Free Trial: Try15Free | applicable once per account
Product Overview
Digestix is a patent-pending dietary supplement targeting gut-derived IL6, a key inflammation driver in Long COVID and chronic disorders like arthritis, autoimmunity, Alzheimer’s, and cancer relapse. Each serving blends 2.5g proprietary oil-sorbent coffee bean fiber, 0.75g activated charcoal, and 3g honey to:
-
Reduce Endotoxin Source: May lower fecal bacterial load, a primary producer of endotoxins linked to IL6 [1].
-
Bind Endotoxins: Coffee fiber and charcoal may reduce endotoxemia, further cutting IL6 production [1].
Formulated for those navigating persistent symptoms, Digestix explores a gut-IL6 link backed by research, not yet proven for Long COVID itself.
How to Use
-
Directions: Take 1-2 sachets before meals, twice daily.
-
Precautions: Do not use if allergic to honey or if you have obstructive bowel disorders. Consult a healthcare provider if unsure.
The Long COVID / COVID Vaccine Side-Effects Connection
Long COVID—fatigue, brain fog, and pain lingering beyond 4 weeks post-infection [2]—is tied to elevated IL6, often from gut endotoxemia [3, 4]. Similarly, COVID19 vaccination in a German study was shown to induce hyper IL6-producing PBMC immune cells regardless of stimulation [11]. IL6 also fuels chronic conditions like rheumatoid arthritis, Alzheimer’s progression, and cancer relapse [5, 8-10]. No proven treatment exists, but studies show dietary fiber can cut IL6 via endotoxin reduction [6]. Digestix builds on this science—with a caveat: it lacks direct clinical trials for Long COVID or these disorders. These statements are not FDA-evaluated; Digestix isn’t intended to diagnose, treat, cure, or prevent any disease.
Our Science-Driven Mission
Inspired by fiber’s IL6-lowering potential [6, 7], Digestix tests a novel approach to gut-driven inflammation [1]. It’s exploratory—not a cure. We’re committed to clinical trials to assess its benefits for Long COVID, cancer, and other high-IL6 states. Your involvement helps us push this research forward.
Pricing & Trial Offer
-
1-Week Free Trial with 15 Sachets (Coupon – Try15Free): Just $34 shipping from Singapore (covers international delivery). No subscriptions, no commitments. Limited to one trial per account; Xylonix reserves the right to refuse orders deemed abusive.
-
1-Month Supply (60 Sachets): $140, free shipping—for those who find it helpful. Limited to 2 orders per month due to small supply.
Available in the US, Australia, and Singapore.
Join the Exploration
Digestix offers a low-risk way to explore relief from Long COVID or IL6-related conditions. Together, let’s navigate the Long COVID / Covid Vaccine Side-Effects challenge. Your trial supports our Long COVID and cancer research—try it, share your experience, and help shape the future of chronic wellness!
References
[1] Cani, P. D., et al. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. doi:10.2337/db06-1491
[2] Crook, H., et al. (2021). Long covid—mechanisms, risk factors, and management. BMJ. doi:10.1136/bmj.n1648
[3] Sirivongrangson, P., et al. (2020). Endotoxemia and circulating bacteriome in severe COVID-19 patients. Intensive Care Med Exp. doi:10.1186/s40635-020-00362-8
[4] Kruglikov, I. L., & Scherer, P. E. (2021). Preexisting and inducible endotoxemia as crucial contributors to the severity of COVID-19 outcomes. PLOS Pathogens. doi:10.1371/journal.ppat.1009306
[5] Rose-John, S. (2012). IL-6 trans-signaling via the soluble IL-6 receptor. Int J Biol Sci. doi:10.7150/ijbs.4989
[6] Ranneh, Y., et al. (2023). Effect of dietary fiber supplementation on metabolic endotoxemia. Methods Protoc. doi:10.3390/mps6050084
[7] Brown, B. I. (2017). Nutritional management of metabolic endotoxemia. Altern Ther Health Med.
[8] Dantzer, R., et al. (2008). From inflammation to sickness and depression. Nat Rev Neurosci. doi:10.1038/nrn2297
[9] Ridker, P. M., et al. (2018). Anti-inflammatory therapy with canakinumab. N Engl J Med. doi:10.1056/NEJMoa1707914
[10] Grivennikov, S. I., & Karin, M. (2011). Inflammatory cytokines in cancer. Ann Rheum Dis. doi:10.1136/ard.2010.140145
[2] Crook, H., et al. (2021). Long covid—mechanisms, risk factors, and management. BMJ. doi:10.1136/bmj.n1648
[3] Sirivongrangson, P., et al. (2020). Endotoxemia and circulating bacteriome in severe COVID-19 patients. Intensive Care Med Exp. doi:10.1186/s40635-020-00362-8
[4] Kruglikov, I. L., & Scherer, P. E. (2021). Preexisting and inducible endotoxemia as crucial contributors to the severity of COVID-19 outcomes. PLOS Pathogens. doi:10.1371/journal.ppat.1009306
[5] Rose-John, S. (2012). IL-6 trans-signaling via the soluble IL-6 receptor. Int J Biol Sci. doi:10.7150/ijbs.4989
[6] Ranneh, Y., et al. (2023). Effect of dietary fiber supplementation on metabolic endotoxemia. Methods Protoc. doi:10.3390/mps6050084
[7] Brown, B. I. (2017). Nutritional management of metabolic endotoxemia. Altern Ther Health Med.
[8] Dantzer, R., et al. (2008). From inflammation to sickness and depression. Nat Rev Neurosci. doi:10.1038/nrn2297
[9] Ridker, P. M., et al. (2018). Anti-inflammatory therapy with canakinumab. N Engl J Med. doi:10.1056/NEJMoa1707914
[10] Grivennikov, S. I., & Karin, M. (2011). Inflammatory cytokines in cancer. Ann Rheum Dis. doi:10.1136/ard.2010.140145
[11] Langgartner, D., Winkler, R., Brunner-Weisser, J. et al. COVID-19 vaccination exacerbates ex vivo IL-6 release from isolated PBMCs. Sci Rep 13, 9496 (2023). https://doi.org/10.1038/s41598-023-35731-2
Graphical Recap of Our Scientific Approach
Reviews
There are no reviews yet.